Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Pediatric-Inspired Pegaspargase Regimen Shows Promise for Treatment of ALL/LBL

A pediatric-inspired treatment regimen incorporating pegaspargase timed to avoid overlapping toxicities was associated with manageable toxicity, high measurable residual disease (MRD) negativity rates, and...

Mogamulizumab Demonstrates Antitumor Activity in Adult T-Cell Leukemia/Lymphoma

Nearly two-thirds of patients with adult T-cell leukemia-lymphoma (ATLL) responded to treatment with mogamulizumab as a single agent or as part of a treatment...

In Oral Maintenance Therapy in AML, Do All Roads Lead to the Epigenome?

Maintenance therapy to reduce relapse of acute myeloid leukemia (AML) and prolong overall survival (OS) has been explored since the 1960s.1 Chemotherapeutic and immunologic...

Azacitidine Tablets Approved for AML Following Chemotherapy

The FDA has approved azacitidine tablets, formerly known as CC-486, for the continued treatment of adults with acute myeloid leukemia (AML) who achieved first...

Venetoclax Combination Granted Full Approval for Newly Diagnosed AML

Venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) has been approved for the treatment of adults with newly diagnosed acute myeloid leukemia...

Evaluating Post-Transplant Sorafenib Maintenance in FLT3-Mutated AML

For patients with acute myeloid leukemia (AML) and an FLT3-ITD mutation, maintenance treatment with the multitargeted tyrosine kinase inhibitor (TKI) sorafenib significantly prolonged relapse-free...
WIB_icon

Is Haploidentical Better Than Cord Blood Transplantation in Leukemia and Lymphoma?

Allogeneic hematopoietic cell transplantation with cord blood or haploidentical bone marrow extend access to transplantation for patients who lack a human leukocyte antigen (HLA)–matched...
WIB_icon

Geriatric Assessment Identifies Risk Factors for Worse Survival in Older Adults With AML

Older patients with acute myeloid leukemia (AML) who undergo post-remission therapy may be at risk of poor survival if they present with impaired physical...
How I Treat In Brief

How I Treat in Brief: Acute Myeloid Leukemia in the Era of New Drugs

Courtney D. DiNardo, MD, and Andrew H. Wei, MD, review recently approved therapies for acute myeloid leukemia and the treatment challenges they present. This material...
On location

Decitabine Plus Venetoclax Outperforms Intensive Chemotherapy Across Risk Groups

For older and unfit patients with acute myeloid leukemia (AML), venetoclax plus hypomethylating agents (HMAs) have been established as a standard of care and...
Advertisement

Current Issue

December 2020, Volume 6, Issue 15

This issue explores non-clinical career opportunities for doctors, hematologic concerns for transgender patients, and more.

Block title